A new major commercial laboratory and research and development centre in the west of Melbourne will advance Victoria’s capabilities in biotechnology, molecular biology and life sciences.
‘ new facility in Ravenhall will generate a $14.9 million investment in the state and create 200 new local jobs including scientists, laboratory technicians and information technology specialists.
This specialised facility will strengthen Victoria’s status as the life sciences hub of Australia, providing analytical testing, research and development and diagnostic manufacturing for clients across a range of industries.
Symbio will produce virus testing kits and molecular biology tests for early cancer diagnosis, as well as invest in advanced medical tools.
This will enhance Victoria’s medical manufacturing capability, reducing reliance on imports and boosting local supply of critical medical products.
Symbio’s investment will see the company expand its service offering and ensure it can rapidly respond to emerging issues in the food, environmental, medical and pharmaceutical sectors – further supporting industry needs.
Symbio will also contribute to Victoria’s workforce development and talent pipeline by partnering with local universities and TAFE institutions to provide 15 internship opportunities each year.
Victoria’s $21.4 billion health technology sector is a global leader in research, testing and manufacturing, employing more than 30,000 people across the state.
